Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)
April 27, 2022 10:39 AM EDT
R&D
Coronavirus

Covid-19 roundup: Pfiz­er-BioN­Tech ask for kid boost­er EUA; No­var­tis, Mol­e­c­u­lar Part­ners may need an­oth­er tri­al for pan­dem­ic ther­a­py

Kyle LaHucik

Senior Reporter

Tyler Patchen

News Reporter

As both the de­bate and pres­sure re­main around giv­ing the youngest chil­dren a first dose of the Covid-19 vac­cine, Pfiz­er and BioN­Tech are mov­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times